FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

PMA: P000027 · Supplement: S027 · Decision Jul 27, 2018
Classifications
1
FEI Numbers
15
Registration Numbers
15

Basic Information

Device Name
Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions
Trade Name
Elecsys free PSA, free PSA CalSet, and free PSA CalCheck
PMA Number
P000027
Supplement Number
S027
Device Class
FDA Class 3
Product Code
MTG
Generic Name
Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions
Medical Specialty
Unknown
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
July 27, 2018
Date Received
August 28, 2017
Supplement Type
Normal 180 Day Track
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

Approval for the migration of Elecsys free PSA, free PSA CalSet and free PSA CalCheck on the cobas e 801 immunoassay analyzer

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MTG Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions